Adjuvant Therapies and Markers of Post-Surgical Minimal Residual Disease I

1. Front Matter

   Pages I-XVIII

   PDF

2. Introduction

   1. Introduction

      • P. Denoix, G. Mathé

      Pages 1-2

3. Incidence, Kinetics and Markers of Post-Surgical Minimal Residual Disease

   1. Front Matter

      Pages 3-3

      PDF

   2. Kinetics of Minimal Residual Disease

      • S. E. Salmon

      Pages 5-15

   3. Ectopic Production of ACTH, Lipotropin, and β-Endorphin by Human Cancer Cells. Structurally Related Tumor Markers

      • X. Y. Bertagna, W. E. Nicholson, K. Tanaka, C. D. Mount, G. D. Sorenson, O. S. Pettengill et al.

      Pages 16-25

   4. Prognostic Value of Postoperative Blood Levels of Carcinoembryonic Antigen (CEA) in Breast Cancer

      • R. E. Myers, D. J. A. Sutherland, J. W. Meakin, D. G. Malkin, J. A. Kellen, A. Malkin

      Pages 26-32

   5. α-Fetoprotein (αFP) as a Marker for Hepatoma and Yolk Sac Tumors

      • D. Buffe, C. Rimbaut

      Pages 33-38

   6. Casein and Breast Cancer

      • J. C. Hendrick, P. F. Zangerle, P. Franchimont

      Pages 39-44

   7. Prostatic Acid Phosphatase and Prostatic Cancer

      • A. G. Foti, J. F. Cooper, H. Herschman

      Pages 45-49

   8. Sialyl Transferase Activity: A Serum Enzyme Marker in the Follow-Up of Cancer Patients

      • U. Ganzinger, K. Moser

      Pages 50-55

   9. Evidence for Natural Antibodies (IgG) to Polyamines in Human Sera

      • A. M. Roch, G. A. Quash, J. P. Ripoll, S. Saez

      Pages 56-62

   10. Dynamic and Composition of Cellular Membranes and Serum Lipids in Malignant Disorders

       • C. Rosenfeld, C. Jasmin, G. Mathé, M. Inbar

       Pages 63-77

   11. Biologic Markers in Neuroblastoma

       • R. Maurus, J. Otten

       Pages 78-84

   12. Immune Complexes in Breast Carcinoma

       • R. W. Baldwin, K. Höffken, R. A. Robins

       Pages 85-87

   13. Serum Leukocyte Inhibitory Factor in Cancer Patients (Serum LIF)

       • A. Fassas, M. Bruley-Rosset

       Pages 88-92

   14. Clinical Evaluation of the Modified Makari Skin Test in Minimal Residual Malignant Disease

       • D. E. H. Tee

       Pages 93-96

   15. Multiparametric Markers in the Monitoring of Cancer

       • E. H. Cooper

       Pages 97-103

4. Adjuvant Therapies of Post-Surgical Minimal Residual Disease

   1. Front Matter

      Pages 105-105

      PDF

   2. Rational and Experimental Basis of Post-Surgical Residual Therapies

      1. A. Rational and Experimental Basis of Post-Surgical Residual Therapies

         • M. Tubiana

         Pages 107-114

      2. Possible Drawback of Radiotherapy: Rational and Experimental Bases of Post-Surgical Therapies

         • J. Stjernswärd

         Pages 115-118

P. Denoix and G. Mathe Approximately 70% of cancer patients relapse after surgery before the 5th year and, in most cases, for example in breast carcinoma, they relapse still later up to the 20th year. For some considerable time, the strategy of cancer treatment has been limited to the sophistication of surgery-radiotherapy combinations that maximally decreased the incidence of local and regional relapses in sites that were within their reach. Today, the practice of clinical oncology is unthinkable without the active participation of the medical oncologist. He is the "third man" of the clinical oncology team, and he has recently focused attention on the fact that most relapses arise from distant metastases due to the proliferation of cells seeded there after having left the primary tumor site at the time of operation and, hence, are inaccessible to any form oflocal and/or regional treatment. On this evidence, medical oncologists have proposed the application of medical treatments for disseminated minimal residual disease (MRD). They have two available means: chemother­ apy and immunotherapy. Medical oncologists in general can be divided into three groups: chemotherapists, immunotherapists, and chemoimmunotherapists. The pure chemotherapists, who had already cured some malignant neoplasias such as Hodgkin's disease, acute lymphoid leukemia, placental choriocarcinoma, and Wilms' tumor, thought they might have the means of attacking the residual disease of common cancers.

• Immunotherapie
• Krebs
• cancer treatment
• carcinoma
• immunotherapy
• leukemia
• lymphocytes
• marker
• metastasis
• microviscosity of lymphocytes
• prostatic acid phosphatimmune
• radioimmunoassay
• radiotherapy
• surgery
• tumor

• Istituto Nazionale dei Tumori, Milano, Italy

  Gianni Bonadonna

• Institut de Cancérologie et d’Immunogénétique, Hôpital Paul-Brousse, Villejuif, France

  Georges Mathé

• University of Arizona Cancer Center, Tucson, USA

  Sydney E. Salmon

Policies and ethics